IL151388A0 - Use of il-18 inhibitors - Google Patents

Use of il-18 inhibitors

Info

Publication number
IL151388A0
IL151388A0 IL15138801A IL15138801A IL151388A0 IL 151388 A0 IL151388 A0 IL 151388A0 IL 15138801 A IL15138801 A IL 15138801A IL 15138801 A IL15138801 A IL 15138801A IL 151388 A0 IL151388 A0 IL 151388A0
Authority
IL
Israel
Prior art keywords
inhibitors
medicament
prevention
preparation
treatment
Prior art date
Application number
IL15138801A
Other languages
English (en)
Original Assignee
Applied Research Systems
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Yeda Res & Dev filed Critical Applied Research Systems
Publication of IL151388A0 publication Critical patent/IL151388A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL15138801A 2000-02-21 2001-02-20 Use of il-18 inhibitors IL151388A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103590 2000-02-21
EP00103597 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
IL151388A0 true IL151388A0 (en) 2003-04-10

Family

ID=27439934

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15138801A IL151388A0 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors
IL151388A IL151388A (en) 2000-02-21 2002-08-21 Use of il-18 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151388A IL151388A (en) 2000-02-21 2002-08-21 Use of il-18 inhibitors

Country Status (30)

Country Link
US (1) US20030157094A1 (cs)
EP (1) EP1257292B1 (cs)
JP (1) JP4744763B2 (cs)
KR (3) KR20070087256A (cs)
CN (1) CN1322897C (cs)
AT (1) ATE506959T1 (cs)
AU (2) AU4063601A (cs)
BG (1) BG66134B1 (cs)
BR (1) BR0108514A (cs)
CA (2) CA2683009C (cs)
CY (1) CY1111687T1 (cs)
CZ (1) CZ304485B6 (cs)
DE (1) DE60144514D1 (cs)
DK (1) DK1257292T3 (cs)
EA (1) EA005583B1 (cs)
EE (1) EE05423B1 (cs)
HR (1) HRP20020652A2 (cs)
HU (1) HU227752B1 (cs)
IL (2) IL151388A0 (cs)
ME (1) ME00546B (cs)
MX (1) MXPA02008079A (cs)
NO (1) NO331971B1 (cs)
NZ (3) NZ535299A (cs)
PL (1) PL206549B1 (cs)
PT (1) PT1257292E (cs)
RS (1) RS51737B (cs)
SI (1) SI1257292T1 (cs)
SK (1) SK288032B6 (cs)
TR (2) TR200502508T2 (cs)
WO (1) WO2001062285A1 (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
IL158866A0 (en) * 2001-05-16 2004-05-12 Yeda Res & Dev Use of il-18 inhibitors for the treatment or prevention of sepsis
WO2003045400A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
US7491803B2 (en) 2003-04-30 2009-02-17 Japan Science & Technology Agency Human anti-human interleukin-18 antibody, fragment thereof and method for using same
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2006003927A1 (ja) 2004-06-30 2006-01-12 Atsuo Sekiyama 非炎症性ストレス応答の指標剤およびその利用
DK1808446T3 (da) * 2004-07-16 2012-05-14 Atsuo Sekiyama IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
SI1885753T1 (sl) 2005-06-03 2011-12-30 Ares Trading Sa Proizvodnja rekombinantnega il-18 vezavnega proteina
US8217152B2 (en) 2005-06-10 2012-07-10 Ares Trading S.A. Process for the purification of IL-18 binding protein
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
SG172625A1 (en) 2006-05-25 2011-07-28 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
EP3978526A1 (en) 2013-09-05 2022-04-06 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
JP7274259B2 (ja) 2015-03-05 2023-05-16 エイビー2 バイオ ソシエテアノニム 炎症性疾患におけるil-18結合タンパク質(il-18bp)および抗体
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
CN112236453A (zh) * 2018-06-14 2021-01-15 波尔多大学 使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
PT936923E (pt) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
YU60402A (sh) 2005-09-19
SK288032B6 (sk) 2012-12-03
SI1257292T1 (sl) 2011-08-31
NZ546294A (en) 2008-02-29
CN1404400A (zh) 2003-03-19
WO2001062285A1 (en) 2001-08-30
EE200200463A (et) 2003-12-15
CA2399298A1 (en) 2001-08-30
KR20070087256A (ko) 2007-08-27
NO20023962L (no) 2002-08-20
KR20020086540A (ko) 2002-11-18
HU227752B1 (en) 2012-02-28
EA005583B1 (ru) 2005-04-28
BR0108514A (pt) 2002-12-17
PT1257292E (pt) 2011-07-05
EE05423B1 (et) 2011-06-15
JP2003523403A (ja) 2003-08-05
NZ535299A (en) 2006-06-30
KR20070057282A (ko) 2007-06-04
NZ520122A (en) 2005-04-29
HRP20020652A2 (en) 2004-12-31
PL357554A1 (en) 2004-07-26
DK1257292T3 (da) 2011-07-18
CA2683009C (en) 2014-09-23
PL206549B1 (pl) 2010-08-31
JP4744763B2 (ja) 2011-08-10
BG66134B1 (bg) 2011-06-30
RS51737B (sr) 2011-10-31
TR200202030T2 (tr) 2003-01-21
MXPA02008079A (es) 2003-02-27
EA200200890A1 (ru) 2003-02-27
BG107018A (bg) 2003-09-30
AU2001240636B2 (en) 2005-10-13
CN1322897C (zh) 2007-06-27
NO20023962D0 (no) 2002-08-20
EP1257292B1 (en) 2011-04-27
AU2001240636B8 (en) 2005-11-03
AU4063601A (en) 2001-09-03
NO331971B1 (no) 2012-05-14
CZ20022843A3 (cs) 2003-02-12
SK12082002A3 (sk) 2003-05-02
CA2683009A1 (en) 2001-08-30
US20030157094A1 (en) 2003-08-21
EP1257292A1 (en) 2002-11-20
ATE506959T1 (de) 2011-05-15
CZ304485B6 (cs) 2014-05-28
ME00546B (me) 2011-10-10
DE60144514D1 (de) 2011-06-09
HK1051965A1 (en) 2003-08-29
TR200502508T2 (tr) 2007-04-24
CA2399298C (en) 2014-04-15
HUP0300061A3 (en) 2005-09-28
IL151388A (en) 2009-09-01
CY1111687T1 (el) 2015-10-07
HUP0300061A2 (hu) 2003-04-28

Similar Documents

Publication Publication Date Title
AU4063601A (en) Use of il-18 inhibitors
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
IL158088A0 (en) Remedies for inflammatory bowel diseases
GB0025173D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
GB0005251D0 (en) Therapeutic compounds
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
EP1116488A3 (en) Treatment of inflammatory Bowel disease
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
MX2009004196A (es) Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes.
EP1669085A4 (en) MEDICAL AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
HUP0300083A3 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
SI1656372T1 (sl) Spojine 2,4-pirimidindiamina za uporabo pri zdravljenju ali preventivi avtoimunih bolezni
EP1194162A4 (en) COMPOSITIONS AND METHODS OF PREVENTING, TREATING AND DETECTING TUBERHULOSIS AND OTHER DISEASES
AU2003282171A8 (en) Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma